Evaluation of the Efficacy of 3-month Continuous Extended Treatment With Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults: a Multicentre Randomised Controlled Trial

Who is this study for? Adults with idiopathic purulent edematous sinusitis
What treatments are being studied? Azithromycin
Status: Recruiting
Location: See all (13) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Purulent Oedematous Sinusitis (POS) is a particular form of chronic rhinosinusitis observed in 2% of the general population. In spite of its heavy impact on the quality of life, There is no established recommendation for the treatment of primary POS. Long-term low-dose macrolides are currently proposed for these forms of chronic rhinosinusitis when conventional treatments (local corticosteroids, saline rinsing, iterative short courses of antibiotics targeted on pathogens, and surgical opening and drainage) have failed. This treatment with macrolides is currently applied off-label. This study aims to assess the efficacy of macrolides in POS. An extensive workup is fulfilled to exclude other forms of chronic rhinosinusitis (Th2 biased inflammatory diseases, allergic diseases) (allergy, nasosinusal polyposis) or those due to cystic fibrosis or immune deficiency.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Patient older than 18 years and less than 70 years of age

• Chronic rhinosinusitis (\> 12 weeks of evolution) meeting the definition published in the European Paper Position2012 (1) and corresponding exclusively to the following endoscopic and CT criteria:

‣ Nasal endoscopy showing bilateral and diffuse involvement associating edema of the mucosa of the nasal cavities and meatus with the presence of mucopurulent secretions in these areas

⁃ Nasosinus CT scan showing diffuse and bilateral pansinus opacities involving at least the maxillary sinuses and the anterior and posterior ethmoids

• Persistent intractable purulent rhinosinusitis despite at least 2 antibiotic therapies

• Signed informed consent of the patient

• Membership in a health insurance plan or beneficiary

Locations
Other Locations
France
CHU Bordeaux
NOT_YET_RECRUITING
Bordeaux
Centre Hospitalier Intercommunal
RECRUITING
Créteil
Hôpital Henri Mondor
RECRUITING
Créteil
CHU Bicêtre, AP-HP
RECRUITING
Le Kremlin-bicêtre
CHU Lille
RECRUITING
Lille
CHU de la Croix Rousse
RECRUITING
Lyon
Hospices de Lyon
RECRUITING
Lyon
Hôpitaux Universitaires de Marseille Conception
RECRUITING
Marseille
CHRU de Nancy
RECRUITING
Nancy
Centre Hospitalier Universitaire De Nantes
RECRUITING
Nantes
CHU Cochin
NOT_YET_RECRUITING
Paris
Hôpital Lariboisiere
RECRUITING
Paris
CHU Toulouse
NOT_YET_RECRUITING
Toulouse
Contact Information
Primary
Emilie BEQUIGNON
emilie.bequignon@chicreteil.fr
0145175000
Backup
Camille JUNG
camille.jung@chicreteil.fr
0145175000
Time Frame
Start Date: 2022-11-21
Estimated Completion Date: 2027-11-21
Participants
Target number of participants: 230
Treatments
Experimental: Azithromycin oral tablet
Azithromycin 250 mg once daily morning or evening (with or without meals)
Placebo_comparator: Placebo
Placebo once daily morning or evening (with or without meals)
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Intercommunal Creteil

This content was sourced from clinicaltrials.gov